comparemela.com

Latest Breaking News On - Therapeutics chairman - Page 1 : comparemela.com

EQS-News: Can This Company s Birth Control Patch Disrupt The Contraceptive Market?

EQS-News: Agile Therapeutics, Inc. Can This Company’s Birth Control Patch Disrupt The Contraceptive Market? 26.10.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. From Evofem Biosciences Inc.’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare B.

United statesMatt rileyAl altomariHead of investor relations corporate communicationsWorld health organizationDrug administrationEvofem biosciences incCan this company birth control patchDistribution servicesAgile therapeutics incDare bioscience incNews serviceAgile therapeuticsEvofem biosciencesDare bioscienceDisruptive contraceptive

EQS-News: Can This Companys Birth Control Patch Disrupt The Contraceptive Market?

EQS-News: Agile Therapeutics, Inc. Can This Companys Birth Control Patch Disrupt The Contraceptive Market? 26.10.2022 / 14:00 CE.

Matt rileyAl altomariHead of investor relations corporate communicationsAgile therapeutics incDare bioscience incWorld health organizationDrug administrationEvofem biosciences incFrom evofem biosciences incDisruptive contraceptiveTherapeutics incTherapeutics chairmanAnnual global investment conferenceCash on hand and the wayPerceptive advisorsAgile therapeutics

Agile Therapeutics streamlines executive team

Women’s health care company Agile Therapeutics Inc. announced Oct. 7 a “reorganized and streamlined” executive team.

Robert conwayAl altomariGeoffrey gilmoreAmy welshPaul kornerJames tursiEndo pharmaceuticalsAgile therapeutics incAntares pharma incAgile therapeuticsAntares pharmaTherapeutics chairman

Agile Therapeutics Acknowledges New Government Guidance

Agile Therapeutics Acknowledges New Government Guidance
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesKimberly whelanMatt rileyAl altomariWomen preventative services guidelinesHuman servicesHealth resourcesDrug administrationDepartment of laborExchange commissionAgile therapeutics incServices administrationWomen preventive services guidelinesSecurities exchangePreventative services guidelinesAffordable care act

Laekna Therapeutics and Innovent Biologics obtain IND approval for combination therapy in patients with specific types of solid tumors who have been refractory to treatment with PD-1/PD-L1 inhibitors

/PRNewswire/ Today, Laekna Therapeutics announced that the investigational new drug (IND) application of a combination therapy for the phase 1/2 clinical.

Shen linChris luYue yongEli lillyUniversity hospitalNational reimbursement drug listDepartment of gastrointestinal oncologyNational medical products administrationCancer instituteLaekna therapeuticsDrug evaluationPrincipal investigatorProfessor shen linVice presidentPeking university hospitalLaekna therapeutic

vimarsana © 2020. All Rights Reserved.